Serum level of soluble CD26/dieptidyl peptidase-4 (DPP-4) activity correlates with other liver disease biomarkers both in Asian and European patients

Translational Research

Volumn 160, Issue 1, 2012, Pages 95-96

  Firneisz, Gabor ^a   Somogyi, Aniko ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; C PEPTIDE; DIPEPTIDYL PEPTIDASE IV; GLUCOSE; HEMOGLOBIN A1C; LIPID; METFORMIN; SITAGLIPTIN; SULFONYLUREA;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIARY CIRRHOSIS; BLOOD GLUCOSE MONITORING; BODY MASS; DIABETIC PATIENT; DIET; DRUG EFFICACY; ENZYME ACTIVITY; EUROPE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEPATITIS C; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; ORAL GLUCOSE TOLERANCE TEST; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEOMICS; TRANSLATIONAL RESEARCH; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84862023512     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2012.01.016     Document Type: Letter

References (15)

1. Y. Aso, N. Ozeki, and T. Terasawa Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea Translational Research 159 2012 25 31
2. G. Firneisz, T. Varga, and G. Lengyel Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker PLoS ONE 5 2010 e12226
3. H. Kobayashi, O. Hosono, and T. Mimori Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus J Rheumatol 29 2002 1858 1866
4. N. Busso, N. Wagtmann, and C. Herling Circulating CD26 is negatively associated with inflammation in human and experimental arthritis Am J Pathol 166 2005 433 442
5. G. Firneisz, P.L. Lakatos, and F. Szalay Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C Scand J Gastroenterol 36 2001 877 880
6. T. Andrieu, V. Thibault, and I. Malet Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections J Clin Virol 27 2003 59 68
7. P.L. Lakatos, G. Firneisz, G. Rákóczy, L. Selmeci, and F. Szalay Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in patients with primary biliary cirrhosis J Hepatol 30 1999 740
8. P.L. Lakatos, G. Firneisz, D. Borcsiczky, A. Zalatnai, L. Selmeci, and F. Szalay Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in experimental liver cirrhosis Eur J Clin Invest 30 2000 793 797
9. G.P. Fadini, M. Albiero, and L. Menegazzo The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients Diabetes Obes Metab 2011 10.1111/j.1463-1326.2011.01550.x
10. E. Mannucci, L. Pala, and S. Ciani Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus Diabetologia 48 2005 1168 1172
11. J. Ryskjaer, C.F. Deacon, and R.D. Carr Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake Eur J Endocrinol 155 2006 485 493
12. S.J. Han, H.J. Kim, and S.E. Choi Incretin secretion and serum DPP-IV activity in Korean patients with type 2 diabetes Diabetes Res Clin Pract 89 2010 e49 e52
13. D. Lamers, S. Famulla, and N. Wronkowitz Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome Diabetes 60 2011 1917 1925
14. H. Yki-Järvinen Type 2 diabetes: remission in just a week Diabetologia 54 2011 2477 2479
15. E.L. Lim, K.G. Hollingswirth, B.S. Aribisala, M.J. Chen, J.C. Mathers, and R. Taylor Reversal of type 2 diabetes: normalization of beta cell function in association with decreased pancreas and liver triacylglycerol Diabetologia 54 2011 2506 2514